President of @FightCRC. Passionate about community engagement, patient empowerment, and social good. #crcadvocacy #CancerSurvivor ๐ช๐ฝ #RelentlessChampions
Joined December 2011
- Tweets 8,446
- Following 1,124
- Followers 1,911
- Likes 18,790
794 Photos and videos
Pinned Tweet
6 Sep 2025
Cancer research is not a line item. Itโs a lifeline. ๐ฌ
@ZEROcancer, @FightCRC, @LUNGevity, @PanCAN, @AACI_Cancer @SusanGKomen join forces to urge sustained federal funding that fuels progress saves lives.
Read the special co-authored Commentary ๐ย conta.cc/3HRf2ab
4
7
856
AnjeeDavis retweeted
New research. New possibilities. ๐ช
We've rounded up the most important #colorectalcancer findings from #ASCO2026 and what they could mean for patients, survivors, and caregivers.
Read the recap: fightcolorectalcancer.org/asโฆ
@ASCO
2
3
1,333
Jun 10
1
21
AnjeeDavis retweeted
Always great to listen to @KimmieNgMD She discussed the Coming Wave of Early-Onset Cancer. With it on the rise we need to do more for these patients. A dedicated program can help with coordination of supportive care service like fertility preservation! @ASCO #ASCO26 @FightCRC
8
14
491
AnjeeDavis retweeted
We need 500 climbers by July 1.
#Climbforacure is going nationwide, and you can join from anywhere.
Free to join. No travel required. Climb your way.
Register today: fightcrc.org/climb
1
2
111
AnjeeDavis retweeted
Come talk to me about patient-reported outcomes! See results of PROs in the ATOMIC A021502 trial - Atezolizumab mFOLFOX6 vs mFOLFOX6 for adjuvant colon cancer. #ASCO26 @ALLIANCE_org
2
9
304
AnjeeDavis retweeted
We all need to do more to incorporate structured exercise program as an affordable & available option to #CRC patients. Thank you for all your work! @CDNCancerTrials Dr. Chris Booth @GillSharlene #ASCO26 #CHALLENGE #CRCSM
#ASCO26 @ASCO
Cost-utility analysis of #CHALLENGE trial of structured #exercise (SEP) after ACT for stage 2-3 colon cancer @CDNCancerTrials ๐จ๐ฆ
๐SEP improves DFS & OS
โก๏ธ SEP is less costly & more effective โWin-Winโ โ
โผ๏ธWe need to implement SEP into routine care ๐ช #NoExcuses
@JCO_ASCO
๐ ascopubs.org/doi/10.1200/JCOโฆ
3
15
868
Jun 1
So proud of @JJSingleton1 for always bravely and authentically sharing his story to ground us that the science represents real lives (people we love) ๐ช๐ฝ๐๐ช๐ฝ @fightcrc @ColonCancerCoal @StupidCancer #asco26
1
3
23
485
AnjeeDavis retweeted
May 31
#ASCO26 Abs LBA #3508: EPISODE-III (JCOG 1503C) randomizes ONLY stage III #coloncancer pts to ASA 100 mg x 3 yrs vs. placebo post adjuvant chemo. Primary endpoint = DFS. #cancer #cancerresearch @OncoAlert
Differs vs. ALASCAA trial (Martling et al; NEJM, 2025)
EPISODE-III
๐Stage III colon
๐PIK3CA MT was not required (PIK3CA MT analysis is ongoing)
๐Adjuvant therapy was required
๐ In unselected patients, ASA 100 mg was not beneficial for DFS
13
23
2,085
AnjeeDavis retweeted
May 30
Kicking off the day at @ASCO with a talk discussing the role of ctDNA across the spectrum of cancer care from early detection to treatment by Valsamo Anagnostou of @HopkinsKimmel!
#ASCO26 #FightCRCRats #cancer @OncoAlert
5
6
726
AnjeeDavis retweeted
May 30
๐จHOT TOPIC: Multicancer Early Detection: Potential Versus Proof results by Mark Robson MD @MSKCancerCenter.
As an advocate do I tell patients to ask for it based on these results? Thoughts are welcome! #CRCTwitter #GITwitter #ASCO26 #FightCRCRats
@ASCO @FightCRC @OncoAlert
1
10
12
721
Jun 1
Thank you so much to the @ColonCancerCoal for their steadfast commitment to collaboration and fighting this disease together ๐ appreciate you so much!!! @EKPPRMPLS and Chris Evans ๐ #strongertogether @fightcrc
1
6
174
AnjeeDavis retweeted
May 31
#ASCO26: LBA #3501- Optimal duration of #adjuvant #chemotherapy (ACT) in resected stage I-IV #colorectal #cancer: Galaxy Japan #ctDNA dynamics.
๐No benefit from continuing ACT if neg
๐ Also suggests no benefit to continue > 3M if neg
๐Rise in ctDNA at 3M suggests do NOT continue
๐For my practice, the role of #ctDNA dynamics will be CONSIDERED as an additional tool during ACT. @asco @OncoAlert
12
24
1,475
AnjeeDavis retweeted
May 31
Our #ASCO26: #BREAKWATER #PFS and #OS results with the FOLFIRI chemo backbone in #BRAFV600E MT #colorectalcancer.
๐PFS: Median 15.2 vs. 8.3M, HR = 0.44
๐ OS: Median NR vs. 20.3M, HR = 0.53
We are so glad to provide another option for our pts!
@PfizerOncMed @ASCO #cancer #cancerresearch @OncoAlert
19
29
1,325
AnjeeDavis retweeted
May 31
@theNCI #SWOG2107 #ASCO26 Phase II of encorafenib cetuximab /- nivo (CMS1) for #BRAFV600MT mCRC. Unfortunately could not validate PFS based on earlier @UTMDAnderson pilot findings. However, it reinforces creating a hypothesis and the need for validation! @VanMorrisMD #cancer #cancerresearch @OncoAlert
5
15
685
AnjeeDavis retweeted
May 31
#ABS #3502 #ASCO26: Observation vs. Maintenance #PD-1 therapy after clinical complete response (cCR) in dMMR/MSI-H managed with #NOM suggesting holding IO therapy at time of cCR does not negatively impact prognosis. @ASCO #cancerresearch @OncoAlert #cancer
9
21
697
AnjeeDavis retweeted
May 31
@ASCO #ASCO26 LBA 3500: DFS and TTR with ctDNA for adjuvant treatment in Stage II colon CA presented by Dr. Folprecht limited by:
๐Low ctDNA only 2.9%
๐ Created 10 yrs ago with limited 81 gene assay
๐ Closed early due to loss of funding
๐Remains prognostic for DFS and OS
@ASCO #cancerresearch #cancer @OncoAlert
7
12
569
Jun 1
Yesterday I met the amazing Dr. LeAnn Bailey to ensure our conversation with the @NCIDirector keeps moving forward ๐ช๐ฝ she is truly a champion for #earlyonsetcolorectalcancer @fightcrc
2
7
329
Jun 1
Only at @ASCO do I get to run into amazing powerhouse women in science ๐งฌ #relentesschampionofhope @KimrynRathmell @CathyEngMD @leanncarter @NCICancerCtrl @fightcrc
2
7
324